Evidence map›Paper›PMID 31906851›Full record

ArticleBMC microbiology2020

In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria.

Vuong Van Hung Le, Catrina Olivera, Julian Spagnuolo, Ieuan G Davies, Jasna Rakonjac

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Virus-Host Interaction GetsInternational journal of molecular sciences · 2021
    Article
  9. Journal of medical microbiology · 2021
    Article
  10. Siderophore Production by Rhizosphere Biological Control BacteriaJournal of microbiology and biotechnology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Vuong Van Hung LeSchool of Fundamental Sciences, Massey University, Palmerston North, New Zealand.
Catrina OliveraSchool of Fundamental Sciences, Massey University, Palmerston North, New Zealand.
Julian SpagnuoloSchool of Fundamental Sciences, Massey University, Palmerston North, New Zealand.
Ieuan G DaviesNew Zealand Pharmaceuticals Ltd, Palmerston North, New Zealand.
Jasna RakonjacSchool of Fundamental Sciences, Massey University, Palmerston North, New Zealand. j.rakonjac@massey.ac.nz.ORCID 0000-0002-6756-4682
Massey University · NZPharmac · NZUniversity Hospital of Basel · CH

Funding

Callaghan Innovation PhD Scholarship (NZ) NoneMassey University, the New Zealand Ministry of Business, Innovation and Employment and New Zealand Pharmaceuticals Ltd None
6 · The paper itself

Abstract

backgroundAntimicrobial combinations have been proven as a promising approach in the confrontation with multi-drug resistant bacterial pathogens. In the present study, we identify and characterize a synergistic interaction of broad-spectrum nitroreductase-activated prodrugs 5-nitrofurans, with a secondary bile salt, Sodium Deoxycholate (DOC) in growth inhibition and killing of enterobacteria.

resultsUsing checkerboard assay, we show that combination of nitrofuran furazolidone (FZ) and DOC generates a profound synergistic effect on growth inhibition in several enterobacterial species including Escherichia coli, Salmonella enterica, Citrobacter gillenii and Klebsiella pneumoniae. The Fractional Inhibitory Concentration Index (FICI) for DOC-FZ synergy ranges from 0.125 to 0.35 that remains unchanged in an ampicillin-resistant E. coli strain containing a β-lactamase-producing plasmid. Findings from the time-kill assay further highlight the synergy with respect to bacterial killing in E. coli and Salmonella. We further characterize the mechanism of synergy in E. coli K12, showing that disruption of the tolC or acrA genes that encode components of multidrug efflux pumps causes, respectively, a complete or partial loss, of the DOC-FZ synergy. This finding indicates the key role of TolC-associated efflux pumps in the DOC-FZ synergy. Overexpression of Nitric Oxide-detoxifying enzyme Hmp results in a three-fold increase in FICI for DOC-FZ interaction, suggesting a role of nitric oxide in the synergy. We further demonstrate that DOC-FZ synergy is largely independent of NfsA and NfsB, the two major activation enzymes of the nitrofuran prodrugs.

conclusionsThis study is to our knowledge the first report of nitrofuran-deoxycholate synergy against Gram-negative bacteria, offering potential applications in antimicrobial therapeutics. The mechanism of DOC-FZ synergy involves FZ-mediated inhibition of TolC-associated efflux pumps that normally remove DOC from bacterial cells. One possible route contributing to that effect is via FZ-mediated nitric oxide production.

Indexed as

Bacterial Outer Membrane ProteinsCitrobacterDeoxycholic AcidDrug Resistance, BacterialDrug SynergismEnterobacteriaceaeEscherichia coliEscherichia coli ProteinsFurazolidoneGene Expression Regulation, BacterialKlebsiella pneumoniaeLipoproteinsMembrane Transport ProteinsMicrobial ViabilityProdrugsSalmonella entericaAcrA protein, E coliBacterial Outer Membrane ProteinsDeoxycholic AcidEscherichia coli ProteinsFurazolidoneLipoproteinsMembrane Transport ProteinsProdrugstolC protein, E coliAntimicrobial combinationEnterobacteriaFurazolidoneNitrofuransSodium DeoxycholateSynergy

Identifiers

PMID31906851
PMCPMC6945529
OpenAlexW3010209973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.